Subscribe to Seeking Alpha feed
https://seekingalpha.com
URL: https://seekingalpha.com
Updated: 21 sec ago

UMH Properties outlines $0.97–$1.05 normalized FFO per share guidance for 2026 while expanding rental program and acquisitions

Thu, 02/26/2026 - 14:28

Aurinia targets $305M–$315M LUPKYNIS sales for 2026 while advancing aritinercept clinical development

Thu, 02/26/2026 - 14:28

ITT Inc. (ITT) Presents at 36th Annual Pump, Valve, and Water Systems Symposium - Slideshow

Thu, 02/26/2026 - 14:28

Credo Q3 Preview: Asymmetry Is The Art Of Alpha

Thu, 02/26/2026 - 14:23

Wendel reports FY results

Thu, 02/26/2026 - 14:21

Adtran outlines $275M-$295M Q1 2026 revenue target as fiber and optical momentum continues

Thu, 02/26/2026 - 14:18

GoodRx expects Pharma Direct revenue growth of at least 30% in 2026 amid shift to pharma manufacturer solutions

Thu, 02/26/2026 - 14:18

Delcath targets at least $100M revenue in 2026 while expanding to 40 treatment centers

Thu, 02/26/2026 - 14:18

Nvidia Keeps Raising The Bar

Thu, 02/26/2026 - 14:11

Novavax outlines $230M–$270M 2026 revenue target with new Pfizer partnership and cost reduction strategy

Thu, 02/26/2026 - 14:09

NCR Voyix outlines $2.21B–$2.325B revenue outlook for 2026 as platform scaling accelerates

Thu, 02/26/2026 - 14:09

Millrose projects $2B invested capital rise outside Lennar in 2026 as platform diversification advances

Thu, 02/26/2026 - 14:09

Global Net Lease outlines $0.80–$0.84 AFFO per share guidance for 2026 while advancing portfolio transformation

Thu, 02/26/2026 - 14:09

Chemed forecasts 5.5%–6.5% VITAS revenue growth and signals 55% of 2026 earnings to be back-half weighted amid transition initiatives

Thu, 02/26/2026 - 14:09

Rhythm anticipates $385M–$415M in 2026 non-GAAP operating expenses as HO launch preparations accelerate

Thu, 02/26/2026 - 14:09

BioCryst outlines $625M–$645M 2026 ORLADEYO revenue target as HAE pipeline advances

Thu, 02/26/2026 - 14:09

Universal Health Services outlines 2026 revenue target of up to $18.8B while accelerating AI and outpatient expansion

Thu, 02/26/2026 - 14:09

Heron Therapeutics outlines $173M–$183M 2026 sales targets amid acute care momentum and expanded commercial investment

Thu, 02/26/2026 - 14:09

NexPoint outlines $0.40–$0.45 Q1 2026 EAD guidance while advancing Life Science and BTR strategies

Thu, 02/26/2026 - 14:09

Emcor outlines $17.75B-$18.5B 2026 revenue target as RPOs hit $13.25B, driven by data center demand

Thu, 02/26/2026 - 14:09

Pages